chronic lymphocytic leukemia

Type: Keyphrase
Name: chronic lymphocytic leukemia
First reported 16 hours ago - Updated 4 hours ago - 10 reports

FDA Approves New Cancer Medication

Zydelig approved to treat certain blood cancersJuly 23, 2014 / Author: / Reviewed by: Joseph V. Madia, MDRate This ArticleAverage Rating3.85Your Rating(dailyRx News) The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat ... [Published Daily Rx - 4 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

FDA approves idelalisib for three leukemia and lymphoma indications

The oral kinase inhibitor idelalisib has been approved for treating patients with relapsed chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma, with a boxed warning... ... [Published Cardiology News - 8 hours ago]
First reported 16 hours ago - Updated 10 hours ago - 4 reports

Zydelig approved for three types of blood cancer

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lym.. ... [Published BioPortfolio - 12 mins ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma ... [Published PR Newswire: Policy & Public Interest - 11 hours ago]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Breakthrough in leukemia

Mr. Smith is a 75-year-old gentleman who was diagnosed with CLL, or chronic lymphocytic leukemia, almost 10 years ago.CLL causes a slow increase in a certain type of white blood cells called B lymphocytes or B cells. Cancer cells spread through the blood ... [Published Citrus County Chronicle - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

ABT-199 rebounds in advanced CLL after tackling tumor lysis syndrome

MILAN – The investigational Bcl-2 inhibitor ABT-199 continues to impress with substantial activity as single-agent or combination therapy in relapsed or refractory chronic lymphocytic leukemia,... ... [Published Cardiology News - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood ... [Published CancerConnect.com - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

PR NewswireNEW YORK July 21 2014NEW YORK July 21...REPORTLINKER.COM ... [Published PharmiWeb - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally ... [Published SearchBug - Jul 21 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

MarketResearchReports.Com: New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, Reveals New Report

Lewes, DE -- (SBWIRE) -- 07/14/2014 -- The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to $3.3 billion by 2018 across six major markets (6MM: the US, France, ... [Published WGNT - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

SummaryChronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current ... [Published Indianapolis Business Journal - Jul 09 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 3 reports

Research and Markets: Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current treatment ... [Published Wall Street Select - Jul 04 2014]

Quotes

"Talk to your pharmacist about emerging treatments for your condition."
"Because of the lack of selectivity of most mechlorethamine analogs, prodrugs, such as phosphoramide compounds, which can be activated by the high concentration of phosphoramidases present in neoplastic cells, have been investigated. Two phosphoramide alkylating agents, cyclophosphamide (CPA) and the isomeric compound Ifosfamide (Ifos) have proved to be particularly effective."

More Content

All (360) | News (268) | Reports (0) | Blogs (80) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Zydelig approved for three types of blood cancer [Published BioPortfolio - 12 mins ago]
FDA Approves New Cancer Medication [Published Daily Rx - 4 hours ago]
ZIOPHARM Oncology : Patent Application Titled "... [Published 4 Traders - 5 hours ago]
Gilead Sciences' (GILD) CEO John Martin on Q2 2... [Published Yahoo! Finance - 5 hours ago]
Gilead pill reaches $3.48B in quarterly sales [Published San Francisco Chronicle - 5 hours ago]
FDA Confirms Approval of Gilead's Zydelig; FDA ... [Published BioMedReports - 8 hours ago]
Healthcare Review: Biogen Idec, Inovio Pharmace... [Published BioMedReports - 8 hours ago]
FDA Approves Indications for Zydelig for Three ... [Published Oncology Times - 8 hours ago]
FDA approves idelalisib for three leukemia and ... [Published Cardiology News - 8 hours ago]
UPDATE 2-Gilead hepatitis C drug Sovaldi racks ... [Published CNBC - 9 hours ago]
Biogen, Gilead Earnings Crush Q2 Estimates [Published Yahoo! Finance - 10 hours ago]
Is Gilead About to Crush Pharmacyclics Stock? [Published Motley Fool Discussion Boards - 10 hours ago]
The Leukemia & Lymphoma Society Applauds FDA's ... [Published CEOWorld Magazine - 11 hours ago]
The Leukemia & Lymphoma Society Applauds FDA's ... [Published PR Newswire: Policy & Public Interest - 11 hours ago]
The Tax Credit That Saves Lives or Wont? [Published Accounting Today - 13 hours ago]
UPDATED: Gilead picks up blockbuster FDA blood ... [Published FierceBiotech - 14 hours ago]
Zydelig Approved for Three Types of Blood Cancer [Published Health Day - 14 hours ago]
UPDATE 1-U.S. FDA approves Gilead blood cancer ... [Published CNBC - 14 hours ago]
Johnson & Johnson Reports 2014 Second-Quarter R... [Published HispanicBusiness.com - 14 hours ago]
Gilead Edges Into Cancer Field With FDA OK of C... [Published Xconomy - 14 hours ago]
Personalised cellular therapy for leukemia rece... [Published European Pharmaceutical Manufacturer - 14 hours ago]
Idelalisib (Zydelig) Approved for CLL and Lymphoma [Published Diabetes Care - 15 hours ago]
Zydelig approved by FDA to treat three types of... [Published Drug Store News - 15 hours ago]
Gilead picks up blockbuster FDA blood cancer ap... [Published FierceBiotech - 15 hours ago]
U.S. FDA approves Gilead's blood cancer drug Zy... [Published CNBC - 16 hours ago]
U.S. Food and Drug Administration Approves Gile... [Published Nasdaq - 16 hours ago]
U.S. Food and Drug Administration Approves Gile... [Published Fort Mills Times - 16 hours ago]
U.S. Food and Drug Administration Approves Gile... [Published Digital Journal - 16 hours ago]
U.S. Food and Drug Administration Approves Gile... [Published Business Wire - 16 hours ago]
Statement from FDA Confirms Approval of Gilead'... [Published Benzinga.com - 16 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Leukemia & Lymphoma Society Applauds FDA's ... [Published PR Newswire: Policy & Public Interest - 11 hours ago]
WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma ...
U.S. Food and Drug Administration Approves Gile... [Published Business Wire Health News - 16 hours ago]
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the treatment of three B-cell blood cancers. Zydelig is indicated ...
EpiCast Report: Chronic Lymphocytic Leukemia - ... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
NEW YORK, July 21, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023... ...
OpportunityAnalyzer: Chronic Lymphocytic Leukem... [Published PR Newswire: Entertainment & Media - Jul 09 2014]
LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to... ...
FDA grants orphan drug status to Eagle's bendam... [Published PBR - News - Jul 09 2014]
The US Food and Drug Administration (FDA) has granted orphan drug designation to Eagle Pharmaceuticals' bendamustine hydrochloride (HCl) for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL). ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TG Therapeutics' Novel Combination of TG-1101 (... [Published GlobeNewswire: Advertising News - Jul 21 2014]
GSK and Genmab Receive EU Authorization for Arz... [Published GlobeNewswire: Nutrition News - Jul 03 2014]
TG Therapeutics Completes Global Licensing Agre... [Published GlobeNewswire: Advertising News - Jun 24 2014]
TG Therapeutics' TG-1101 (Ublituximab) in Combi... [Published GlobeNewswire: Acquisitions News - Jun 13 2014]
GSK and Genmab Receive CHMP Positive Opinion fo... [Published GlobeNewswire: Acquisitions News - May 23 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.